Fact & Figures Boehringer Ingelheim RCV
Facts and figures speak a clear language. Only economic success enables us to implement our corporate vision. It is an important indicator of whether our strategies and ideas are also accepted by our partners and society.
Boehringer Ingelheim Regional Center Vienna (RCV)
Facts and Figures RCV 2022
| in million EUR | 2022 | 2021 |
|---|---|---|
| Prescription Medicine | 1.127,5 | 987,1 |
| Animal Health | 187,7 | 166,1 |
| Total turnover (3rd parties) | 1.315,2 | 1.153,2 |
| Operational performance*) | 2.244,1 | 1.796,8 |
| Sales Revenue **) | 2.067,8 | 1.752,7 |
| Investments | 148,0 | 179,6 |
| Number of Employees | 5.169 | 5.090 |
*) Operating performance of Boehringer Ingelheim RCV GmbH & Co KG includes net sales, operating sales, and inventory changes. It also contains sales from affiliated companies, including the sales from biopharmaceutical business in Vienna.
**) Sales of Boehringer Ingelheim RCV GmbH & Co KG also include sales to affiliated companies, including revenues from the Vienna Biopharmaceuticals business.
Facts and Figures Austria 2022
| in million EUR | 2022 | 2021 |
|---|---|---|
| Prescription Medicine | 119,7 | 116,2 |
| Number of Employees in Austria | 3.388 | 3.096 |
Other Regional Center Vienna (RCV) facts:
- Business responsibility for 33 countries
- Boehringer Ingelheim worldwide cancer center since 2000
- Long-standing main sponsor of the Vienna Research Institute of Molecular Pathology (IMP)
Other Group facts:
- Sales revenue 2022: 24,1 billion EUR
- Products sold in 130 countries
- More than 53,000 employees
- Annual research investment of around 5 billion EUR